With much of the world at various levels of lockdown for most of 2020, face to face interaction has been hugely restricted for clinical trials. For many, this has meant either the postponement of studies, or a rapid adoption of decentralized or hybrid trials.
At the same time, clinical trials have taken on huge importance in the development of both treatment and a vaccine for COVID-19, moving through phases faster than ever before.
Over the following pages, dozens of clinical trials experts offer their insights into both these impacts of the pandemic.